Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

Underlying mechanisms and drug intervention strategies for the tumour microenvironment, Journal of Experimental & Clinical Cancer Research

Overview of clinical trials assessing treatments for ovarian cancer

Visual Abstract on LinkedIn: #visualabstract #visualabstracts #lungcancerresearch #bonemetastasis…

Targeting by PG545 enhances PARP inhibitor response in ovarian cancer

Cancers, Free Full-Text

Inhibition of tumor growth and metastasis by PG545 in AsPC-1 orthotopic

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Effects of PG545 and gemcitabine treatment on pancreatic cancer cells.

A) Co-treatment of QC and autophagy inhibitor Bafilomycin A in C13

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review - Gynecologic Oncology

Complementary anti-cancer pathways triggered by inhibition of sideroflexin 4 in ovarian cancer